Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.
Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T; REVIVE Heart Failure Study Group. Packer M, et al. Among authors: delgado herrera l. JACC Heart Fail. 2013 Apr;1(2):103-11. doi: 10.1016/j.jchf.2012.12.004. Epub 2013 Apr 1. JACC Heart Fail. 2013. PMID: 24621834 Free article. Clinical Trial.
A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy.
Zhang W, Kernstock RM, Karrer EE, Cohen SB, Chindalore VL, Kivitz AJ, Blahunka PC, Delgado-Herrera L, Zeiher BG, Samberg NL, Garg JP. Zhang W, et al. Among authors: delgado herrera l. Clin Pharmacol Drug Dev. 2016 Jul;5(4):259-68. doi: 10.1002/cpdd.237. Epub 2016 Jan 8. Clin Pharmacol Drug Dev. 2016. PMID: 27310327 Clinical Trial.
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients.
Zhu T, Keirns J, Howieson C, Kaibara A, Goldwater R, Kivitz AJ, Chindalore V, Cohen S, Santos V, Akinlade B, Kernstock R, Delgado-Herrera L, Blahunka PC, Karrer EE, Garg JP, Samberg N, Zeiher BG. Zhu T, et al. Among authors: delgado herrera l. Clin Pharmacol Drug Dev. 2016 Sep;5(5):408-25. doi: 10.1002/cpdd.251. Epub 2016 Mar 28. Clin Pharmacol Drug Dev. 2016. PMID: 27410490 Clinical Trial.
Cultural adaptation: translatability assessment and linguistic validation of the patient-reported outcome instrument for irritable bowel syndrome with diarrhea.
Delgado-Herrera L, Lasch K, Popielnicki A, Nishida A, Arbuckle R, Banderas B, Zentner S, Gagainis I, Zeiher B. Delgado-Herrera L, et al. Patient Relat Outcome Meas. 2016 Jun 22;7:81-92. doi: 10.2147/PROM.S102647. eCollection 2016. Patient Relat Outcome Meas. 2016. PMID: 27382346 Free PMC article.
Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population.
Delgado-Herrera L, Lasch K, Zeiher B, Lembo AJ, Drossman DA, Banderas B, Rosa K, Lademacher C, Arbuckle R. Delgado-Herrera L, et al. Therap Adv Gastroenterol. 2017 Sep;10(9):673-687. doi: 10.1177/1756283X17726018. Epub 2017 Aug 24. Therap Adv Gastroenterol. 2017. PMID: 28932269 Free PMC article.
Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents.
Preusser LC, Fryer RM, Gerhardt A, Hu Y, Delgado-Herrera L, Melnick JZ, Williams LA, Cox BF, Reinhart GA. Preusser LC, et al. Clin Exp Pharmacol Physiol. 2005 Dec;32(12):1020-6. doi: 10.1111/j.1440-1681.2005.04299.x. Clin Exp Pharmacol Physiol. 2005. PMID: 16445566
15 results